Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.
... Read More
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review processes updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information on this review, please consult the CADTH website.
This CADTH update primarily ... Read More
REGISTRATION IS OPEN!
Learn how the new PMPRB amendments and guidelines will affect your pharmaceutical pricing, negotiations and reimbursement
Join PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, for industry-only sessions on the pricing guidelines, led by senior members ... Read More
Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.
Summary of New pCPA Activity Since ... Read More
Mark your calendar: On Wednesday, November 6th at 11:00 a.m., the Canadian Real-World Evidence for Value of Cancer Drugs (CanReValue) team will host a webinar to present the development and testing of a framework that will be used to generate and apply real-world evidence (RWE) in funding decisions for ... Read More
3Sixty Public Affairs and PDCI Market Access have collaborated to create an infographic that unmasks the reality behind the assumptions Health Canada has used to justify its ongoing drug pricing reforms (through the Patented Medicine Prices Review Board). When it comes to federal drug pricing reform in Canada, there is ... Read More
PDCI is very pleased to welcome Keeley Farrell to the PDCI Team as Analyst, HTA and Clinical Evaluation.
Keeley will help to support the development and preparation of the evidence-based clinical components of reimbursement and pricing submissions. She will also conduct research to support market access and ... Read More
Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.
SUMMARY OF NEW PCPA ACTIVITY SINCE AUGUST ... Read More
In July 2019, CADTH announced a new round of public consultations on its Pharmaceutical Review Programs. CADTH’s proposed changes would affect how it manages, reviews and reconsiders information submitted by pharmaceutical manufacturers through its Common Drug Review. Stakeholders were invited to submit feedback on three consultations:
Proposal to Enhance ... Read More
REGISTRATION IS OPEN!
Learn how the new PMPRB amendments and guidelines will affect your pharmaceutical pricing, negotiations and reimbursement
Join PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, for industry-only sessions on the pricing guidelines, led by senior members of the PDCI team ... Read More
